Cathepsin K, a cysteine protease expressed in osteoclasts, degrades type 1 collagen.
Odanacatib selectively and reversibly inhibited cathepsin K and rapidly decreased bone …

The selective cathepsin K inhibitor odanacatib (ODN) progressively increased bone mineral
density (BMD) and decreased bone‐resorption markers during 2 years of treatment in …

Inhibition of cathepsin K (CatK) is a potential new treatment for osteoporosis. In two double‐
blind, randomized, placebo‐controlled phase I studies, postmenopausal female subjects …

Odanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal
osteoporosis. Phase 2 data indicate that 50 mg once weekly inhibits bone resorption and …

Odanacatib is a cathepsin K inhibitor developed for the treatment of postmenopausal
osteoporosis. It is a bone resorption inhibitor, but which preserves bone formation to some …

Odanacatib (ODN) is a selective inhibitor of the collagenase cathepsin K that is highly
expressed by osteoclasts. In this 2‐year, phase 2, dose‐ranging trial, postmenopausal …

Aims To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
odanacatib (ODN), a cathepsin K inhibitor, in humans. Methods Two double‐blind …

Osteoporosis is a disease of high bone remodeling with an imbalance of bone resorption
over bone formation, resulting in decreased bone mineral density and deterioration of bone …

Background Odanacatib, a cathepsin K inhibitor, reduces bone resorption while maintaining
bone formation. Previous work has shown that odanacatib increases bone mineral density in …

Cathepsin K (CatK) is a cysteine protease abundantly expressed by osteoclasts and
localized in the lysosomes and resorption lacunae of these cells. CatK is the principal …